Analysis of DOC and Ram for NSCLC

Background: Current clinical trials demonstrated that combination regimens comprising chemotherapy and immunotherapy lead to better patient outcomes compared to chemotherapy alone as the first line of treatment for non-small cell lung cancer (NSCLC). In addition, the combination therapy of docetaxel (Doc) and ramucirumab (Ram) was considered one of the standard treatments for advanced or relapsed NSCLC patients. However, little is known about the therapeutic responders of this combination therapy among previously treated NSCLC patients. In the present study, we aimed to identify predictive factors for therapeutic response, including programmed death-ligand 1 (PD-L1) expression in tumors, for Doc treatment in combination with Ram. Methods: We retrospectively analyzed a total of 135 advanced or relapsed NSCLC patients who were refractory to platinum-based chemotherapy at eleven institutions in Japan between July 2016 and November 2018. Results: Our observations showed that PD-L1 expression in tumors is not associated with the efficacy of combined therapy of Doc and Ram in previously treated NSCLC patients. Analysis of the patient clinical profiles indicated that prior treatment with immune checkpoint inhibitors (ICIs) is a reliable predictor for the good progression-free survival (PFS) to this combination therapy (P=0.041). Conclusions: Our retrospective study indicated that combination regimens comprising chemotherapy and ICIs followed by Doc and Ram could be an optimal therapeutic option for NSCLC patients regardless of the PD-L1 status of tumors. Further investigations are required to strengthen clinical evidence demonstrating the effectiveness of the combination therapy of Doc plus Ram in previously treated NSCLC patients

[16]Oと[10, 11]Bとの弾性散乱および核子移行反応

京都大学0048新制・課程博士理学博士理博第137号新制||理||96(附属図書館)2261京都大学大学院理学研究科原子核理学専攻(主査)教授 武藤 二郎, 教授 小林 稔, 教授 柳父 琢治学位規則第5条第1項該当Kyoto UniversityDA

Executing Verified Compiler Specification

Abstract. Much work has been done in verifying a compiler specification, both in hand-written and mechanical proofs. However, there is still a gap between a correct compiler specification and a correct compiler implementation. To fill this gap and obtain a correct compiler implementation, we take the approach of generating a compiler from its specification. We verified the correctness of a compiler specification with the theorem prover Isabelle/HOL, and generated a Standard ML code corresponding to the specification with Isabelle’s code generation facility. The generated compiler can be executed with some hand-written codes, and it compiles a small functional programming language into the Java virtual machine with several program transformations.

Immunotactoid Glomerulopathy with Nontuberculous Mycobacterial Infection: A Novel Association

A 70-year-old woman underwent a renal biopsy due to nephrotic syndrome. She had suffered from nontuberculous mycobacterial infection (NTM) for 14 years. The patient was diagnosed as having membranoproliferative glomerulonephritis (MPGN) type 3 and immunoglobulin (Ig)-associated MPGN based upon LM/erythromycin and IF findings, respectively. In high-magnification imaging, electron-dense deposits showed immunotactoid glomerulopathy (ITG). There was no evidence of hematological cancer, and the patient improved after receiving treatments for NTM. To the best of our knowledge, this patient is the first to show an association between ITG and NTM. Although ITG is generally considered as related to lymphoproliferative disease, it is suggested that ITG is driven by bacterial infection and is a potential outcome of Ig-associated MPGN